Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
Lung cancer is the leading cause of cancer-related death worldwide due to late diagnoses and limited treatment interventions. Recently, comprehensive molecular profiles of lung cancer have been identified. These novel characteristics have enhanced the understanding of the molecular pathology of lung...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fonc.2017.00193/full |
id |
doaj-24033570234b45c68eeeecc734889b4a |
---|---|
record_format |
Article |
spelling |
doaj-24033570234b45c68eeeecc734889b4a2020-11-25T00:57:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2017-08-01710.3389/fonc.2017.00193270057Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO ClassificationKentaro Inamura0Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, JapanLung cancer is the leading cause of cancer-related death worldwide due to late diagnoses and limited treatment interventions. Recently, comprehensive molecular profiles of lung cancer have been identified. These novel characteristics have enhanced the understanding of the molecular pathology of lung cancer. The identification of driver genetic alterations and potential molecular targets has resulted in molecular-targeted therapies for an increasing number of lung cancer patients. Thus, the histopathological classification of lung cancer was modified in accordance with the increased understanding of molecular profiles. This review focuses on recent developments in the molecular profiling of lung cancer and provides perspectives on updated diagnostic concepts in the new 2015 WHO classification. The WHO classification will require additional revisions to allow for reliable, clinically meaningful tumor diagnoses as we gain a better understanding of the molecular characteristics of lung cancer.http://journal.frontiersin.org/article/10.3389/fonc.2017.00193/fulladenocarcinomadriver mutationgenetic alterationhistologymolecular pathologylung cancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kentaro Inamura |
spellingShingle |
Kentaro Inamura Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification Frontiers in Oncology adenocarcinoma driver mutation genetic alteration histology molecular pathology lung cancer |
author_facet |
Kentaro Inamura |
author_sort |
Kentaro Inamura |
title |
Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification |
title_short |
Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification |
title_full |
Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification |
title_fullStr |
Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification |
title_full_unstemmed |
Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification |
title_sort |
lung cancer: understanding its molecular pathology and the 2015 who classification |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2017-08-01 |
description |
Lung cancer is the leading cause of cancer-related death worldwide due to late diagnoses and limited treatment interventions. Recently, comprehensive molecular profiles of lung cancer have been identified. These novel characteristics have enhanced the understanding of the molecular pathology of lung cancer. The identification of driver genetic alterations and potential molecular targets has resulted in molecular-targeted therapies for an increasing number of lung cancer patients. Thus, the histopathological classification of lung cancer was modified in accordance with the increased understanding of molecular profiles. This review focuses on recent developments in the molecular profiling of lung cancer and provides perspectives on updated diagnostic concepts in the new 2015 WHO classification. The WHO classification will require additional revisions to allow for reliable, clinically meaningful tumor diagnoses as we gain a better understanding of the molecular characteristics of lung cancer. |
topic |
adenocarcinoma driver mutation genetic alteration histology molecular pathology lung cancer |
url |
http://journal.frontiersin.org/article/10.3389/fonc.2017.00193/full |
work_keys_str_mv |
AT kentaroinamura lungcancerunderstandingitsmolecularpathologyandthe2015whoclassification |
_version_ |
1725223082180739072 |